COMPASS PATHWAYS PLC Operating Lease Right-of-Use Assets
COMPASS PATHWAYS PLC (CMPS) had Operating Lease Right-of-Use Assets of $3.94 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $3.94M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.86M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $3.42M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $3.93M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $3.94M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $2.86M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.42M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.93M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $4.34M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $1.46M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.01M 10-K · filed 2026-03-24 |
| 2024-09-30 | $2.75M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $3.18M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $3.72M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $4.31M 10-K · filed 2025-02-27 |
| 2023-09-30 | $4.17M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.78M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.59M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.01M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.34M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.09M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.06M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $3.70M 10-K · filed 2023-02-28 |
| 2021-01-01 | $1.00M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |